CYGB and cancer: Finally, we have taken into account the patients’ discrepancies in clinicopathological characteristics, treatment program and cancer type, and proved that the association between HGB levels and ICI treatment outcomes is independent of these factors, particularly those established biomarkers of immunotherapy response.